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Abstract
Background: Palliative Care Day Services (PCDS) offer supportive care to people with advanced, progressive illness
who may be approaching the end of life. Despite the growth of PCDS in recent years, evidence of their costs and
effects is scarce. It is important to establish the value of such services so that health and care decision-makers can
make evidence-based resource allocation decisions. This study examines and estimates the costs and effects of
PCDS with different service configurations in three centres across the UK in England, Scotland and Northern Ireland.
Methods: People who had been referred to PCDS were recruited between June 2017 and September 2018. A
pragmatic before-and-after descriptive cohort study design analysed data on costs and outcomes. Data on costs
were collected on health and care use in the 4 weeks preceding PCDS attendance using adapted versions of the
Client Service Receipt Inventory (CSRI). Outcomes, cost per attendee/day and volunteer contribution to PCDS were
also estimated. Outcomes included quality of life (MQOL-E), health status (EQ-5D-5L) and capability wellbeing
(ICECAP-SCM).
Results: Thirty-eight attendees were recruited and provided data at baseline and 4 weeks (centre 1: n = 8; centre 2:
n = 8, centre 3: n = 22). The cost per attendee/day ranged from £121–£190 (excluding volunteer contribution) to
£172–£264 (including volunteer contribution) across the three sites. Volunteering constituted between 28 and 38%
of the total cost of PCDS provision. There was no significant mean change at 4 week follow-up from baseline for
health and care costs (centre 1: £570, centre 2: -£1127, centre 3: £65), or outcomes: MQOL-E (centre 1: − 0.48, centre
2: 0.01, centre 3: 0.24); EQ-5D-5L (centre 1: 0.05, centre 2: 0.03, centre 3: − 0.03) and ICECAP-SCM (centre 1:0.00,
centre 2: − 0.01, centre 3: 0.03). Centre costs variation is almost double per attendee when attendance rates are
held constant in scenario analysis.
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Conclusions: This study highlights the contribution made by volunteers to PCDS provision. There is insufficient
evidence on whether outcomes improved, or costs were reduced, in the three different service configurations for
PCDS. We suggest how future research may overcome some of the challenges we encountered, to better address
questions of cost-effectiveness in PCDS.
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Background
Palliative care day services (PCDS) have developed to
support people with life-limiting illness, who are able to
attend a centre on a regular basis for symptom manage-
ment, and emotional, psychological and social support
[1, 2]. Typically, PCDS provide some core support
services and respite for family carers [3]. PCDS in the
UK are under the purview of four Departments of
Health across the constituent countries: England,
Scotland, Wales and Northern Ireland, but are not
directly managed by them. They are delivered by organi-
sations (typically charities) engaged to provide services.
Although professional codes of practice apply across the
UK and National Care Standards cover management,
staff, and premises [4–6], as a devolved responsibility,
health and social care service provision differs across the
four countries, which contributes to local variation in
how PCDS are delivered [7, 8].
Despite the growth of PCDS over the past 20 years in
the UK, evidence of their costs and effects is limited.
Where there is evidence, it has been collected in London
and the South East of England in the main, and there is
considerable variation in cost estimates for many types
of palliative care services [9]. For example, a study
conducted in 1999 involving five centres in Southern
England found that PCDS cost around £79 (2018 value)
per person per day, rising to £109 (2018 value) if
unfunded resources (volunteer time) were included [10].
More recent estimates in a 2010/11 single-centre study
in London put the cost of a day hospice attendance
(excluding volunteer time) at £158 (2018 value) [11].1
It is unclear whether PCDS acts as a substitute for or a
complement to other services to meet unmet need, an
important issue when considering the impact of service
on total costs. In one prospective quasi-experimental
study of a hospice in the South East of England, PCDS
were found to supplement rather than replace or reduce
provision of other community and hospital services [12],
and it did not provide details of any additional costs of
day services used by attendees. Earlier work has, how-
ever, suggested that PCDS might substitute for home
nursing or GP care and that PCDS provided in 1999
were not available elsewhere [10]. Quantitative data on
the effectiveness of PCDS is also scarce [2].
We set out to examine and estimate the costs and
effects of PCDS across a broader geographical area, to
inform a more comprehensive view of PCDS across the
UK.
Methods
Setting
We chose three services where dedicated research staff
were available and had existing links to the research
team. These links enabled an initial mapping exercise to
be conducted to understand how these services were
configured. This background information highlighted
commonalities and differences between the services
across the three sites and provided the context for the
planning of the study design. We thus recruited
attendees from three hospices delivering PCDS, one in
each from England, Scotland and Northern Ireland. Each
service offered a different mix of medical, nursing and
allied healthcare, alongside social and psychological
support. Centres operated between three to 5 days per
week, with 12–15 places available per day and an
average mean daily attendance of between 6 and 12
people [13].
Study design
A pragmatic before-and-after descriptive cohort study
was conducted involving people attending PCDS and
those nominated by them as close persons, namely
family and their close friends or informal carers [14]. To
assure quality and safety, research governance approval
was obtained at each hospice/centre (both terms used
interchangeably here). Research ethics approval was
granted by the NHS Health Research Authority West
Midlands - Solihull Research Ethics Committee
(reference: 17/WM/0100).
Sample
Eligible participants were people consecutively referred
to PCDS as out-patients or as part of a supportive
approach to in-patient care. Inclusion was dependent on
sufficient performance and cognitive functioning scores
as assessed by nursing staff during attendees’ first visit to
the PCDS centre using clinical judgement and validated
1Costs taken from previous studies are adjusted to 2018 net present
values using the UK Treasury Gross Domestic Product (GDP) deflator.
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tools (e.g. we excluded individuals with an Australian
Karnosky Performance Scale Index ≤40 [15], or an
ECOG Scale of Performance Status ≥3 [16], or an Ab-
breviated Mental Test ≤6 [17]). Participants were given
the choice of completing the measures independently,
together with a nominated close person, or with the help
of a researcher. People were not eligible to participate if
they had insufficient command of the English language
to complete consent and data requirements, were aged
under 18 or, to focus upon the intended population
living at home, if they had been referred from a care
home. Informed consent was given by attendees and
close persons prior to data collection. A Participant
Information Sheet and Letter of Introduction about the
study were provided and discussed with a researcher
before participants agreed to take part in the study and
sign a consent form. Thereafter, a ‘process’ approach
was adopted, whereby patient consent was confirmed on
a continuing basis throughout the study [18]. Attendees
were asked to nominate a close person and were given a
letter, which provided an introduction to the study, to
pass on to their close person. Participation in the study
was not dependent on the recruitment of a close person.
Data
To achieve the study objectives and based upon prior re-
view of PCDS attendance, 9 months were allocated for
data recruitment to achieve a sample size of 113 at-
tendees and 113 close persons across the three centres
at baseline (centre 1 n = 45, centre 2 n = 27 and centre 3
n = 41), with 50% of participants expected to remain in
the study for 12 weeks (i.e. n = 57). This was not based
on a specific sample size calculation due to the study
design, but was based on what was believed to be prag-
matically achievable across the three centres (i.e. 50% of
all new attendees in each centre over 9 months), as well
as drawing from recruitment undertaken in similar
settings previously [19, 20].
PCDS attendees and close persons provided basic
demographic information and data on health and care
usage in the previous month using three adapted
versions of the Client Service Receipt Inventory (CSRI)
[21], to reflect the different services at the three centres
and allow for variation in job role descriptions in
England, Northern Ireland and Scotland. Attendance at
PCDS ranged from 8 to 12 weeks duration. Attendees
and close persons provided data at up to four time
points (baseline, 4 weeks, 8 weeks and, where possible, at
12 weeks follow-up). Quality of life, health status and
capability wellbeing measures were collected using the
tools below:
 An expanded version of the McGill Quality of Life
Questionnaire (MQoL-E), scored on a 0–10 worst-
best quality of life scale, featuring eight subscales
(physical, psychological existential, social, burden,
environmental, cognition, healthcare) across 20
items. The MQOL-E was designed to comprehen-
sively measure the subjective quality of life of a
person with a life-threatening illness [22];
 Generic health status was measured using the EQ-
5D-5L, containing five dimensions (mobility, self-
care, usual activities, pain/discomfort and anxiety/
depression) across five levels of severity problems
[23]. Values for EQ-5D-5L are generated from the
EQ-5D-3L UK general population crosswalk [24,
25]. EQ-5D-5L values are anchored on a 0–1 scale,
representing dead - perfect health [26].
 A measure specifically developed to capture the
benefits of end of life care in economic evaluation,
the ICECAP-SCM, has seven domains covering
choice/having a say in decision-making, love and af-
fection/being with people who care, freedom from
physical suffering, freedom from emotional suffering,
dignity and self-respect, support and preparation
[27]. The ICECAP-SCM main effects tariff from the
general UK population was applied. ICECAP-SCM
values are anchored on a 0–1 scale, representing no
capability at the end of life – full capability at the
end of life [28].
Two measures, used primarily in health economic ana-
lysis, were included, because the EQ-5D-5L has been
shown to have little in common with outcomes relevant
for palliative care [29] and patients and close persons
feel outcomes such as the opportunity for a good death
are more appropriate (e.g. ICECAP-SCM) [30].
There are two broad types of costing approaches: top-
down or bottom-up. A top-down approach involves
identifying the total costs of a programme or service and
apportioning those costs to the components involved in
its delivery. A bottom-up approach identifies and mea-
sures individual components of a service in a disaggre-
gated way [31]. Both approaches were used, however,
given the smaller than anticipated sample size, it was not
possible to determine the costs of the PCDS from the
prospective data alone. Consequently, a scoping exercise
of service provision and use at the three PCDS sites was
undertaken in 2015 [13]. The findings were combined
with the cohort data and information provided by the
key contacts at each centre to estimate the total cost per
attendee/day at each PCDS using the top-down
approach. Health and care costs reported in the CSRI
were taken from the cohort data only using bottom up
costing.
The economic valuation of resource use data required
a combination of methods. Costs for the PCDS were
based on cost per attendance. This was estimated using
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information on resource use available in the hospices,
including information on the delivery of day hospice,
such as staffing and volunteer mix. Health care and so-
cial services resource use, staffing, volunteering and
mileage was valued using the Unit Costs of Health and
Social Care 2018 edition [32]. Minimum wage costs were
applied when volunteering roles were unavailable as an
equivalent market rate for such roles, a common ap-
proach when calculating the economic cost of volunteer
time [33]. All costs are valued in pound sterling (GBP)
in the year 2018.
Data analysis
Due to a smaller than anticipated sample, the analysis is
concentrated on examination of complete cases of PCDS
attendees at the three centres. The differences in costs
and outcomes at four-week follow up, compared to base-
line and comparison of costs per day attendance at
PCDS across the three centres, are analysed. This was
done to focus on the most complete data available.
Paired t tests [34] were conducted to assess the differ-
ence in mean outcome and cost data at the four-week
follow up compared to baseline at the three centres. Sig-
nificance level was set to 5 and 95% confidence intervals
were estimated for the differences between paired costs
and outcomes at the centre level. A scenario analysis,
examining cost per attendee/day using three hypothet-
ical attendance rates (100, 80 and 60%) was conducted
to investigate the variation in costing within and across
the three PCDS.
Results
Table 1 describes the staffing and volunteer composition
of the three PCDS centres. It also includes information
on the operation of PCDS, in terms of days open, places
available for attendees per day, and the attendance rates
of the three centres in 2015. It details the staff and vol-
unteer composition of the three centres in 2018/19.
Participants were recruited between June 2017 and
September 2018 across the three centres (centre 1 from
June to October 2017 and from July to September 2018;
centre 2 from January to March 2018; centre 3 from
January to June 2018). There were inconsistencies
between start and finish time at each site, due to local
differences in approval dates. Data collection at centre 1
was interrupted due to staff changes. Due to larger than
anticipated recruitment difficulties, a decision was made
during recruitment to stop data collection at 12 weeks
for attendees and all data collection for close persons.
In total 56 attendees completed baseline data (centre 1
n = 16, centre 2 n = 9, centre 3 n = 31), 38 at 4 weeks
(centre 1 n = 8, centre 2 n = 8, centre 3 n = 22), 31 at 8
weeks (centre 1 n = 6, centre 2 n = 7, centre 3 n = 18),
and 16 at 12 weeks (centre 1 n = 1, centre 2 n = 6, centre
3 n = 9). Most attendees requested help from the
researcher to complete the questionnaires. For close per-
sons, the total sample at baseline was 22 (centre 1 = 9,
centre 2 = 5, centre 3 = 8), 14 at 4 weeks (centre 1 = 4,
centre 2 = 5, centre 3 = 5), 10 at 8 weeks (centre 1 = 3,
centre 2 = 4, centre 3 = 3) and 9 at 12 weeks (centre 1 =
1, centre 2 = 5, centre 3 = 3). The results focus on
attendee cases with complete data at baseline and 4
weeks (n = 38).
Table 2 reports descriptive statistics for the 38 partici-
pants for whom there was follow-up data at 4 weeks.
Most participants were aged over 65 at the time of re-
cruitment (age range in years for centre 1: 57–81; centre
2: 51–91; centre 3: 41–88), white, living in owner occu-
pied homes, were married, did not live alone and had a
cancer diagnosis. This is consistent with the wider popu-
lation of those referred to hospice services [35]. The
source of referral and the average time from diagnosis to
commencing PCDS varied between the centres.
The mean cost per attendee/day ranged from £121 to
£190 across the three centres (Table 3). Including volun-
teer costs raises the average cost per attendee/day to
£172 to £264 across the three centres. Volunteering
constituted between 28 and 38% of the total costs of
PCDS provision.
Table 4 reports changes in non-hospice health and
care resource use and changes in outcome over 4 weeks.
There were no statistically significant differences in the
costs and outcomes between the three PCDS at follow-
up. The direction of the mean changes in costs and
outcomes across the centres, with the varied geograph-
ical locations of and differences in service provision, do
not form a consistent pattern.
A scenario analysis of the cost per attendee/day esti-
mated by varying attendance rates demonstrates a large
variation in costs across scenarios and centres (Table 5).
The costs for centre 1 are almost twice those of centre
3, whether volunteer contribution is included or not.
Discussion
The mean cost of providing PCDS across the three
centres ranged from £121 to £190 per attendee/day. The
cost of providing PCDS is considerably higher when the
value of volunteering is accounted for, raising it to be-
tween £172 to £264 per attendee/day (Table 3). There
was also variation in how individual PCDS centres oper-
ationalised services, in particular, the staffing mix being
considerably higher at centre 1 compared to centres 2
and 3, resulting in the cost per attendee/day at centre 1
being almost double those at centres 2 and 3, when at-
tendance rates are held constant (Table 5). As illustrated
in our scenario analysis (Table 5), one way of minimising
the current cost per attendee/day and maximising the
number of attendees accessing PCDS would be to
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increase attendance rates across all centres within exist-
ing staffing and volunteering resources. It would be im-
portant to ensure, however, that this did not reduce the
quality of PCDS provided. The analysis from this cohort
study is exploratory and we were unable to conclude
whether PCDS reduces other health and care costs or
improves outcomes, when using a generic health status
measure (EQ-5D-5L), a capability wellbeing near the end
of life measure (ICECAP-SCM) or a quality of life during
a life-threatening illness measure (MQOL-E) (Table 4).
A strength of this study is the use of data from three
centres with different service configurations serving local
communities which together were reflective of the wider
diverse UK population. All sites were research ready
environments, with site-specific research governance
procedures in place and had participated in previous
research projects. The study is limited by the small
sample size and it was not possible to compare the three
services. The recruitment figures were affected by
unforeseen delays in recruiting research staff, a delay in
securing ethical approval, and well documented difficul-
ties involved in recruiting to studies of palliative care
[36].
The five main challenges we experienced to varying
degrees were [37]:
(1) ensuring participant identification through
understanding the inclusion and exclusion criteria;
(2) excessive participant burden in data collection;
(3) limited staff time;
(4) clinical deterioration in participants and
(5) complexity in caregiver involvement.
(1) PCDS operates in a flexible way with more repeat
visits than new cases: here, we limited our inclusion of
new attendees at their first attendance, aiming to capture
each episode of care from the start, leading to a slow
start as we did not include current caseload but waited
Table 1 Composition of three Palliative Care Day Services (PCDS) centres in the UK
Centre 1 Centre 2 Centre 3 Notes
PCDS Operation in 2015 A
Days in operation per week 5 3 5 A
Sites where PCDS in operation 3 1 1 A,B
Places available per day 15 12 15 A
Attendance rate 75% 56% 60% A
Staff in 2018/19 (Proportion of FTE) C
Manager - social worker 1.0 D
Manager - nurse 1.0 D
Manager - allied health professional 0.6 D
Associate Specialist Doctor 0.4 D
Nurse consultant 0.2 D
Social worker 0.6 D
Palliative care nurse 1.0 D
Occupational therapist 1.0 0.6 0.2 D
Physiotherapist 1.0 0.2 D
Registered nurse 1.0 0.6 1.0 D
Rehabilitation assistant 0.6 D
Health Care Assistant 1.0 D
Secretary 1.0 D
Volunteers in 2018/19 (Proportion of FTE)
Complementary therapists 2.0 0.2 0.4 D
Drivers 3.0 3.6 2.4 E
Hospitality 3.0 1.8 2.8 E
Hairdresser 0.25 E
A. Operational data from a mapping exercise of the three centres in 2015 - see [13]; B. Centre 1 operates 3 days a week at the main site and at two satellite units
running one day a week each; Centre 2 now operates 5 days a week, with a satellite unit running two days a week; C. Staff and volunteer numbers providing from
the three centres in 2018/19; D. From [32]; E. minimum wage rate for 2017/18 applied (£15,269 per year): source Office for National Statistics; FTE
full-time equivalent
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to recruit new referrals. (2) It is inevitable that data cap-
ture requires time and effort by participants and this af-
fected the data collection. Indeed, we set out to obtain
several repeated measures and this may have been too
difficult as participants’ health deteriorated and it
seemed attrition was inevitable. However (3) shortage of
staff time and (4) client deterioration were not deemed
to cause concern with PCDS, a relatively well-staffed
and early-stage intervention. (5) Close-person involve-
ment was difficult to achieve because of caregiver dis-
tress, the practicalities of obtaining dual consent, and a
lack of recognition on the part of the close persons of
the value of the study. In addition, many could not find
time to participate.
The accuracy of the costing was also affected by the
small sample size, in particular in centres 1 and 2, so
data were drawn from 2015 PCDS models of service de-
livery [13] to compensate for the limited data collected.
Careful interpretation of results is essential given poten-
tial biases arising from missing data [38]. There are sev-
eral options for managing missing data in economic
analyses [39] but the sample size in this study precluded
their application. Analysis of cohort study data was con-
ducted using complete case analysis.
A systematic review on the costs of palliative care in
the UK highlighted the variation in estimates in different
studies [9]. Our study found that costs for PCDS also
vary across centres and across the UK, with differences
in staff mix, volunteer mix and attendance rates all iden-
tified as elements of this variation. Our study suggests
the costs of providing PCDS may have been underesti-
mated in earlier work [10, 11]. However, it does confirm
the extensive and significant role volunteers play in the
provision of PCDS [10], even though volunteer time is
not routinely included in health and care economic eval-
uations in the UK [40]. Volunteers’ roles in PCDS are
wide ranging, and include complementary therapy,
beauty therapy/hairdressing and pastoral/faith based care
services [41], offering a distinct contribution, and in
many cases assuming the characteristics of a paid em-
ployee [42]. Exclusion of volunteers from costing PCDS
Table 3 Cost per attendee/day at three Palliative Care Day Services in the UK
Centre Costs excluding volunteer contribution Costs including volunteer contribution
1 £190 £264
2 £164 £263
3 £121 £172
Table 2 Characteristics of attendees from the three PCDS centres included in analysis
Centre 1 Centre 2 Centre 3 Total (%)
Sample size (n) 8 8 22 38 (100%)
Average mean age (years) 66 75 68 69
Male (%) 7 4 9 20 (53%)
White ethnicity (%) 6 8 19 33 (87%)
Married (%) 5 4 11 20 (53%)
Living alone (%) 3 4 6 13 (34%)
Owner occupied homes (%) 5 6 16 27 (71%)
Cancer diagnosis (%) 7 3 14 24 (63%)
Average time since diagnosis (years) 1 5 4 4
Referral source (%)
Hospital consultant 8 8 (21%)
Hospice community nurse 4 4 8 (21%)
Clinical nurse specialist 3 5 8 (21%)
GP 1 1 2 (5%)
Respiratory service 5 5 (13%)
Specialist palliative care team 2 2 (5%)
Occupational therapist 2 2 (5%)
Within hospice referral 2 2 (5%)
Not available 1 1 (3%)
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underestimates both the economic costs of providing
PCDS and the value of the volunteers’ time.
The gap between the number of staff needed in health
and care in England alone and those available could reach
more than 350,000 by the year 2030 if the number of staff
leaving the workforce early continues and recruitment of
newly trained staff and international recruits does not in-
crease [43]. This also has implications for hospice services
and has been identified as a key priority by Hospice UK
which is committed to working with hospices and partner
organisations to develop sustainable solutions to meet
these workforce challenges [44]. This suggests the contri-
bution of volunteers to hospice services may become an
even more important issue in workforce planning. When
we included the value of volunteering in the costs for pro-
viding PCDS, we found that 28–38% of costs per at-
tendee/day was volunteer contribution to PCDS delivery
at these three centres across the UK. It is important to dis-
cover if this constitutes a ‘critical mass’ in terms of the
staff skill mix in such services, or if there is scope for ex-
pansion. Indeed, a recent study concluded there is scope
for hospices to develop strategic aspects of volunteering
through greater community engagement and involvement
[45]. Moreover, it was recognised some years ago that
there was a need to increase recruitment to expand the
volunteer workforce, and that hospices need to be sup-
ported by more effective and extensive deployment of
volunteers [46]. However, it is interesting to note that in a
later workforce policy statement [44] there was no indica-
tion of how this will be achieved. Our findings provide
useful detail for those addressing workforce issues at a
policy and practice level.
No significant change in costs and effects at any of the
three centres after 4 weeks were indicated by the cost
and outcomes data (Table 4), but these results must be
regarded as exploratory only. Thus, one key aspect yet to
be determined is whether the provision of PCDS repre-
sents a good investment for improving attendee out-
comes for PCDS providers or by reducing costs for
health and care services as a whole. This question is not
only important to commissioners and providers of PCDS
in offering value for money and to attendees who may
benefit from such services, but also to ensure that the
contribution of PCDS staff and volunteers is being man-
aged effectively to maximise the benefit of the service
they offer. Further work is needed to establish the bene-
fits and costs of PCDS. For example, quasi-experimental
designs have been used in a similar setting where rando-
mised controlled trials were not feasible, and similar de-
signs could potentially be used to evaluate PCDS [12].
Future research would also be beneficial to assess the
costs and outcomes for close persons of PCDS attendees
to see if benefits of PCDS extend beyond the attendee
[47].
Table 5 Scenario Analysis of cost per attendee/day
Excluding Volunteer Costs Including Volunteer Costs
Attendance Rate Centre 1 Centre 2 Centre 3 Centre 1 Centre 2 Centre 3
100% £142 £91 £73 £199 £149 £107
80% £177 £114 £91 £247 £185 £131
60% £236 £152 £121 £327 £244 £172
Table 4 Change in health and care resource use and attendee outcome at 4 week follow-up
Cost/outcome Centre n Baseline 4 week Change (95% CIs)
Health and care costs 1 7 £1508 £2078 £570 (−£1155, £2255)
2 8 £1920 £793 -£1127 (−£2642, £388)
3 22 £1187 £1252 £65 (−£946, £1076)
MQOL-E 1 8 7.11 6.64 −0.48 (−1.72, 0.76)
2 8 6.88 6.89 0.01 (−0.70, 0.72)
3 22 5.97 6.21 0.24 (−0.29, 0.77)
EQ-5D-5L 1 7 0.38 0.43 0.05 (− 0.19, 0.29)
2 8 0.43 0.46 0.03 (−0.14, 0.19)
3 22 0.59 0.56 −0.03 (− 0.17, 0.11)
ICECAP-SCM 1 8 0.87 0.87 0.00 (−0.07, 0.07)
2 8 0.90 0.89 −0.01 (− 0.03, 0.02)
3 22 0.80 0.83 0.03 (−0.02, 0.07)
CIs confidence intervals; MQOL-E is scored on a 0–10 worst-best quality of life scale; EQ-5D-5L is scored on a 0–1 dead-perfect health scale; ICECAP-SCM is scored
on a 0–1 no capability at the end of life-full capability at the end of life scale
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Conclusions
This study highlights the important contribution of
volunteers to PCDS provision. We found there was
insufficient evidence to draw conclusions about whether
outcomes improve, or costs reduce, in the three different
service configurations for PCDS. We provide suggestions
for future research that is needed to overcome some of
the challenges we encountered in this study to better
address questions concerning the cost-effectiveness of
PCDS.
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